Astrazeneca (AZN) Non-Current Debt (2009 - 2026)

Astrazeneca's Non-Current Debt history runs 18 years deep, the most recent figure standing at -$24.5 billion for Q1 2026.

• In Q1 2026, Non-Current Debt rose 8.38% year-over-year to -$24.5 billion; the TTM figure through Mar 2026 stood at -$24.5 billion (up 8.38% YoY), while the FY2025 annual figure was -$24.7 billion, down 193.24% from the prior year.
• Non-Current Debt was -$24.5 billion for Q1 2026 at Astrazeneca, up from -$24.7 billion in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $26.5 billion in Q4 2024 to a low of -$28.9 billion in Q3 2024.
• Historically, Non-Current Debt has averaged -$16.9 billion across 5 years, with a median of -$24.7 billion in 2025.
• The sharpest annual moves came in 2024 and 2025: Non-Current Debt advanced 18.52% in 2024, then tumbled 193.24% in 2025.
• A 5-year view of Non-Current Debt shows it stood at $23.0 billion in 2022, then fell by 2.61% to $22.4 billion in 2023, then grew by 18.52% to $26.5 billion in 2024, then sank by 193.24% to -$24.7 billion in 2025, then increased by 1.06% to -$24.5 billion in 2026.
• The last three Non-Current Debt figures came in at -$24.5 billion (Q1 2026), -$24.7 billion (Q4 2025), and -$24.7 billion (Q3 2025), per Business Quant data.